Glycopyrrolate

This page follows the US label for glycopyrrolate oral tablets, 1 mg and 2 mg.

The label lists one use: in adults, to reduce symptoms of a peptic ulcer as an add-on to ulcer treatment.

It is not indicated as the only treatment, because healing of ulcers has not been shown.

The Indian lists we checked also include injection and other forms for use before surgery. Those uses are not covered by this label.

• Adult peptic ulcer symptoms (add-on treatment only)

The label says glycopyrrolate is an anticholinergic (antimuscarinic) agent.

It blocks acetylcholine on stomach parietal cells and reduces the volume and acidity of gastric secretions.

The US label for adults gives different schedules by tablet strength.

For the 1 mg tablet, the initial dosage is 1 mg three times daily (morning, early afternoon and bedtime). Some people may need 2 mg at bedtime. For maintenance, 1 mg twice daily is often enough.

For the 2 mg tablet, the label lists 2 mg two or three times daily at evenly spaced intervals.

The maximum daily dosage the label lists is 8 mg, and it says to use the lowest dose that controls symptoms.

The label says the 2 mg tablet is not meant for starting treatment or for maintenance when a 1 mg dose is enough.

Indian pack labels may differ from the US label. Your prescriber's instruction always comes first. Do not change the dose yourself.

The label contraindicates glycopyrrolate with glaucoma, urinary obstruction (including enlarged prostate), mechanical gut obstruction, gut motility disorders, bleeding gastrointestinal ulcer, active colitis, toxic megacolon and myasthenia gravis, or allergy to it.

Older adults: the label says tablets are not recommended in geriatric patients and may be contraindicated in some, because of urinary retention, bowel obstruction, heat prostration, arrhythmias, delirium and falls.

Heat: the label warns of heat prostration (fever and heat stroke), so avoid hot or very warm environments.

Driving: the label says it may impair mental or physical function, so avoid driving or hazardous tasks until you know how it affects you.

Kidneys: monitor people with renal impairment for anticholinergic side effects.

Pregnancy: human data are absent, and animal studies at non-toxic doses showed no developmental harm. Ask your doctor.

Breastfeeding: no data on milk or the infant, and it may suppress lactation, as other anticholinergics do.

Children: safety and effectiveness have not been established.

The label excerpt we reviewed does not describe alcohol. Ask your doctor or pharmacist.

• Glaucoma, urinary or gut obstruction, colitis, myasthenia gravis: contraindicated
• Older adults: not recommended by the label
• Avoid hot environments
• Do not drive until you know how it affects you
• Take care with kidney disease and heart disease

• Other anticholinergic medicines
• Antipsychotics
• Solid oral potassium chloride
• Medicines whose absorption depends on gut movement
• The label says it is not recommended with other anticholinergic medicines, as effects add up.
• Examples include tricyclic antidepressants, antiepileptics, class I antiarrhythmics, antispasmodics and amantadine.
• Taking it with antipsychotics may worsen tardive dyskinesia.
• Slowed gut movement can change the absorption of other medicines, so the label does not recommend use with those affected.
• It is not recommended with solid oral forms of potassium chloride, because slow gut movement may worsen gut injury.

No match in this label text. Ask your pharmacist about any medicine you take.

The label says overdose gives excess anticholinergic effects such as flushing, high temperature, fast heartbeat, ileus, urinary retention and light sensitivity.

Brain effects such as agitation and seizures may also occur.

The label advises contacting a poison control centre. In India, go to the nearest hospital emergency department.

The label says to store at 20 to 25 degrees C.

It should be kept in a tight, light-resistant container with a child-resistant closure.

In the Drugs Rules 1945 schedules we checked, Glycopyrrolate appears as Schedule H, serial 230 (rules 65 and 97).

The National List of Essential Medicines 2022 lists these forms: Injection 0.2 mg/mL; Tablet 7.5 mg; Nasal Spray 0.5mg.

The National Pharmaceutical Pricing Authority (NPPA) lists ceiling prices for the formulations in the table below. A seller cannot charge more than the ceiling per unit.

We found no mention of Glycopyrrolate in the banned-combination list we checked.

The ceiling price is the most a seller may charge per unit for a scheduled formulation. Actual brand prices are usually at or below it. Check the pack and seller for the real price.

Jan Aushadhi (PMBJP) product rows we found for Glycopyrrolate are listed next.

Glycopyrrolate Injection IP 0.2mg, pack 1 ml.

Glycopyrrolate Tablet 1Mg, pack 10's.

Glycopyrrolate Tablet 2Mg, pack 10's.

We do not show a brand price here. Prices change, so confirm with the seller.